The Australian and Avance Clinical Advantage is all about the rapid start-up, leveraging 43.5% rebates to reduce costs, and delivering internationally accepted quality data from world-leading clinical settings, KOLs and PIs.
No IND required:
Our biotech clients start their Phase I without having to wait for an IND, saving up to a year in regulatory timelines and considerable costs.
Rapid IRB/EC approval:
Our clients are currently experiencing a 3-week IRB/EC turnaround due to the supportive regulatory and clinical environment, and Avance Clinical’s experience.
Avance Clinical data is accepted by all the major regulatory authorities including the FDA and EMA.
With almost 50% of adults vaccinated, Australia has prioritized clinical research as an essential service which supports Avance Clinical’s biotech clients, clinical sites, and patients seeking access to therapies.
Proven site network across Australia and New Zealand:
Avance Clinical has a powerful Australian and New Zealand network of proven PIs and clinical sites.
5-6 week start-up:
With the Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks it enables you to get access to clinical data quickly and gain that critical Go/No Go information on your product faster than anywhere else in the world.